Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9578 posts found.

hiv-infected_h9_t-cell_-_credit_national_institutes_of_health-web

HIV successfully overcomes CRISPR gene-editing technology

April 8, 2016 Research and Development HIV, crispr, failure, setback

Researchers using the CRISPR gene-editing technology have indicated that HIV can defeat efforts to cripple it, but have characterised it …
News
fda2outsideweb

US panel supports accelerated approval for Intercept’s trial drug for rare liver condition

April 8, 2016 Medical Communications, Research and Development, Sales and Marketing Intercept Pharmaceuticals, PDUFA, US FDA, liver disorder, rare disease

Intercept Pharmaceuticals (Nasdaq: ICPT) said a US Food and Drug Administration (FDA) advisory committee has recommended accelerated approval for its …
News
genome

UK’s genomics and personalised medicine expertise showcased at major international gathering

April 8, 2016 Manufacturing and Production, Research and Development 000 genomics project, 100, NHS, UK, expertise, genomics, international gathering, world leader

The UK’s expertise in genomics was showcased at a major international gathering to foster global collaboration in this burgeoning field. …
News

Pfizer, IBM partner to develop monitoring system for Parkinson’s disease

April 8, 2016 Medical Communications, Research and Development Parkinson's disease, Pfizer, collaboration, ibm, research, technology

US pharma giant Pfizer (NYSE: PFE) and International Business Machines Corp (NYSE: IBM) have partnered on a research project focussed on …
News

Vectura to get $10 million milestone as Hikma files ANDA for generic copy of GSK’s asthma drug

April 8, 2016 Medical Communications, Research and Development, Sales and Marketing

Vectura Group (LSE: VEC) on Friday said it is set to receive $10 million in milestone payments from partner Hikma …
News

Sandoz receives EU approval for subcutaneous injection of Binocrit biosimilar

April 8, 2016 Medical Communications, Research and Development Sandoz, binocrit, biosimilar, eu approval

Sandoz has received approval from the European Commission for a type II variation for the addition of a subcutaneous route …
News
bi_centre_03_2

Boehringer Ingelheim’s Giotrif gets Europan regulatory backing in another lung cancer indication

April 7, 2016 Business Services, Research and Development, Sales and Marketing Boehringer Ingelheim, European Commission, giotrif, lung cancer

German drugmaker Boehringer Ingelheim on Thursday said European regulators have granted marketing rights for its non-small cell lung cancer (NSCLC) …
News
clinical_trial_4

Clinical trials initiated for novel immunotherapy combo for ovarian cancer

April 7, 2016 Medical Communications, Research and Development MedImmune, cancer research institute, clinical trial, ludwig, ovarian cancer, ventirx

A cross collaboration between industry and not-for-profit organisations will see Ludwig Cancer Research and the Cancer Research Institute partner with …
News
eli_lilly_logo

Incyte buys rights to Eli Lilly’s Ruxolitinib; shares jump

April 7, 2016 Research and Development, Sales and Marketing Eli Lilly, Incyte, Licencing, M&A, MA, Novartis

Shares in Incyte Corp (Nasdaq: INCY) soared to close up over 11.5% Wednesday as the company said it has purchased …
News
foundry

UK’s first commercial synthetic biology foundry begins production

April 7, 2016 Manufacturing and Production, Research and Development Biological, biologics, foundry, synbicite

SynbiCITE’s has begun production at the UK’s first commercial synthetic biology foundry. The site provides automated end-to-end design, construction and …
News
handshake

Allergan to partner with Heptares in Alzheimer’s disease collaboration

April 7, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Allergan, Alzheimer's, Heptares, R&D, collaboration, commercialisation, h1, h4, neurological disorders, partnership, research and development, treatments

Bouncing back quickly from the collapse of the collapse of the Pfizer inversion deal, Allergan (NYSE:AGN) has announced a new …
News

Novartis receives EU approval for blood disorder treatment in children

April 7, 2016 Research and Development, Sales and Marketing EMA, EU, ITP, Novartis, Revolade, approval, blood disorder, children, chronic itp

Novartis (NYSE: NVS) has announced that Revolade (eltrombopag) has been approved in the EU for use in paediatric patients aged …
News
pfizer_building

5 things to know about the Pfizer/Allergan inversion collapse

April 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 5, 5 things, Allergan, Pfizer, collapse, inversion, reasons

The end came very quickly for the Pfizer/Allergan $160 billion deal once the US Treasury Department announced a new set …
Feature
jj_sign_on_wall

Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million

April 6, 2016 Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research

Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …
News
allergan

Allergan, Pfizer confirm termination of $160 billion merger

April 6, 2016 Business Services, Research and Development, Sales and Marketing

Botox maker Allergan Plc (NYSE:AGN) and US pharma giant Pfizer (NYSE: PFE) on Wednesday confirmed they have terminated the merger …
News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026